ArticleJournal of clinical hypertension (Greenwich, Conn.)2025
Effect of Age on Aldosterone-Renin Ratio in Screening Primary Aldosteronism.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Primary Hyperaldosteronism: Epidemiology, Diagnosis, and Clinical Associations.Epidemiologia (Basel, Switzerland) · 2026Review
- Optimal Cut-Off Values of the Aldosterone-Renin Ratio in Different Age Groups for Primary Aldosteronism Screening.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Revisiting renin-angiotensin-aldosterone system in aging: translational insights from bench to bedside and back.The Journal of clinical investigation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism (PA) is the most common endocrine cause of hypertension. The plasma aldosterone-to-renin ratio (ARR) is the most recommended screening tool for PA, but previous studies showed controversy regarding the influence of age on ARR. The aim of the study was to evaluate the impact of age on ARR measured using direct renin concentration (DRC) and its diagnostic value in patients with PA. We retrospectively collected patients with hypertension who attended Xiangya Hospital for PA screening using plasma aldosterone concentration (PAC)/DRC from January 1, 2017 to November 1, 2023. The patients were divided into the groups of PA and essential hypertension (EH) by confirmatory tests. We performed separate correlation analyses of age and DRC, PAC, and ARR, the patients were then further subdivided into four age groups: < 40, 40-49, 50-59, and ≥ 60 years old. Receiver operating characteristic curve and area under the curve (AUC) were used to determine age-specific ARR cutoff values for screening PA. We screened a total of 478 patients, comprising 255 diagnosed with PA (53.35%) and 176 with EH (36.82%). In patients with EH, PAC and DRC decreased with increasing age (p < 0.001, r = -0.34; p < 0.001, r = -0.28), whereas ARR increased with age (p = 0.002, r = 0.22). However, in patients with PA, DRC, PAC, and ARR did not show significant association with age (p = 0.40, 0.54, 0.33). The cutoff values of ARR for screening PA in four groups were 17.49, 20.79, 21.01, and 18.22. The optimal ARR cutoff was 22.52 in the all-ages, with an AUC of 0.948 (95% CI: 0.929, 0.966), sensitivity of 89.4%, and specificity of 85.2%. There was no significant correlation between age and DRC or PAC in patients with PA. Compared to the consensus-recommended cutoff of 37 (pg / mL)/(μIU/mL), a lower ARR cutoff may be more appropriate for screening PA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.